Allogene Therapeutics, Inc. (ALLO) financial statements (2020 and earlier)

Company profile

Business Address 210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:589721
Cash and cash equivalents17592
Short-term investments355367
Other undisclosed cash, cash equivalents, and short-term investments58262
Prepaid expense53
Other undisclosed current assets(50)(257)
Total current assets:545468
Noncurrent Assets
Property, plant and equipment569
Long-term investments and receivables63262
Long-term investments63262
Intangible assets, net (including goodwill)01
Intangible assets, net (excluding goodwill)01
Restricted cash and investments41
Other noncurrent assets50
Other undisclosed noncurrent assets4433
Total noncurrent assets:173306
TOTAL ASSETS:718774
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities912
Accounts payable912
Deferred compensation liability35
Other liabilities31
Other undisclosed current liabilities1812
Total current liabilities:3329
Noncurrent Liabilities
Liabilities, other than long-term debt414
Deferred compensation liability, classified 7
Other liabilities47
Other undisclosed noncurrent liabilities5128
Total noncurrent liabilities:5641
Total liabilities:8971
Stockholders' equity
Stockholders' equity attributable to parent629703
Common stock00
Additional paid in capital1,024914
Accumulated other comprehensive income10
Accumulated deficit(396)(212)
Total stockholders' equity:629703
TOTAL LIABILITIES AND EQUITY:718774

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Operating expenses(202)(193)
Operating loss:(202)(193)
Nonoperating income (expense)17(19)
Other nonoperating income176
Interest and debt expense (3)
Loss from continuing operations before equity method investments, income taxes:(185)(215)
Other undisclosed income from continuing operations before income taxes 3
Loss from continuing operations before income taxes:(185)(212)
Income tax benefit00
Net loss available to common stockholders, diluted:(185)(212)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(185)(212)
Other comprehensive loss(0)(0)
Comprehensive loss:(185)(212)
Other undisclosed comprehensive income, net of tax, attributable to parent10
Comprehensive loss, net of tax, attributable to parent:(184)(211)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: